文献速递物质与行为成瘾

每周丁丙诺啡缓释剂CAM2038对阿片使用障碍患者的氢吗啡酮阻断效应:一项随机临床试验

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

该多中心双盲随机自身对照研究纳入47例DSM-V中重度阿片使用障碍(OUD)非治疗寻求者,评估每周皮下注射丁丙诺啡缓释剂CAM2038(24 mg或32 mg)阻断氢吗啡酮欣快效应及抑制戒断症状的能力。结果显示两种剂量均产生即时且持续的阻断效应和戒断抑制,药代动力学特征支持每周给药,安全性良好。

要点

  • 每周CAM2038 24 mg和32 mg均即时且持续阻断氢吗啡酮的欣快效应(P<.001)。
  • 两种剂量均显著抑制阿片戒断症状(P<.001),安全性良好。
  • CAM2038血药浓度约24小时达峰,表观半衰期4-5天,支持每周一次给药。

核心结论

  • 每周CAM2038 24 mg和32 mg安全耐受,产生即时且持续的阿片阻断和戒断抑制。
  • 结果支持该缓释剂型用于OUD患者的治疗启动和稳定,并可避免每日丁丙诺啡的误用和转移风险。

研究设计与样本

  • 多中心、双盲、随机、自身对照研究,在3个受控住院研究机构进行。
  • 纳入47例DSM-V中重度OUD的非治疗寻求成人,随机分配至CAM2038每周24 mg(n=22)或32 mg(n=25)。
  • 共5个3天测试阶段,评估对氢吗啡酮(0、6、18 mg肌内注射,随机顺序,每阶段每天1剂)的反应。
  • 研究时间为2015年10月12日至2016年4月21日,46/47例随机参与者完成研究。

主要发现

  • 氢吗啡酮喜好最大效应:CAM2038 24 mg效应量0.813(P<.001),32 mg效应量0.753(P<.001)。
  • 临床阿片戒断量表:CAM2038 24 mg效应量0.617(P<.001),32 mg效应量0.751(P<.001)。
  • CAM2038血浆丁丙诺啡约24小时达峰,表观半衰期4-5天,首次至第二次给药谷浓度约50%蓄积。
  • 谷浓度:24 mg第1周0.822 ng/mL、第2周1.23 ng/mL;32 mg第1周0.993 ng/mL、第2周1.47 ng/mL。

关键数值与推荐

  • 主要终点为药物喜好视觉模拟量表的最大评分。
  • 次要终点包括其他视觉模拟量表(如high和用药欲望)、阿片戒断量表及生理和药代动力学结局。

临床怎么用

  • 每周CAM2038 24 mg或32 mg可用于OUD患者的治疗启动和稳定。
  • 缓释剂型可保留丁丙诺啡疗效的同时避免每日口服制剂的误用和转移风险。

局限性

  • 研究为非治疗寻求的OUD个体,样本量47例,结论外推需谨慎。
  • 研究在受控住院环境进行,真实世界依从性和疗效可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may be obviated by a sustained release formulation. OBJECTIVE: To evaluate the ability of a novel, weekly, subcutaneous buprenorphine depot formulation, CAM2038, to block euphorigenic opioid effects and suppress opioid withdrawal in non-treatment-seeking individuals with OUD. DESIGN, SETTING, AND PARTICIPANTS: This multisite, double-blind, randomized within-patient study was conducted at 3 controlled inpatient research facilities. It involved 47 adults with DSM-V moderate-to-severe OUD. The study was conducted from October 12, 2015 (first patient enrolled), to April 21, 2016 (last patient visit). INTERVENTIONS: A total of five 3-day test sessions evaluated the response to hydromorphone (0, 6, and 18 mg intramuscular in random order; 1 dose/session/day). After the first 3-day session (ie, qualification phase), participants were randomized to either CAM2038 weekly at 24 mg (n = 22) or 32 mg (n = 25); the assigned CAM2038 dose was given twice, 1 week apart (day 0 and 7). Four sets of sessions were conducted after randomization (days 1-3, 4-6, 8-10, and 11-13). MAIN OUTCOMES AND MEASURES: The primary end point was maximum rating on the visual analog scale for drug liking. Secondary end points included other visual analog scale (eg, high and desire to use), opioid withdrawal scales, and physiological and pharmacokinetic outcomes. RESULTS: A total of 46 of 47 randomized participants (mean [SD] age, 35.5 [9] years; 76% male [n = 35]) completed the study. Both weekly CAM2038 doses produced immediate and sustained blockade of hydromorphone effects (liking maximum effect, CAM2038, 24 mg: effect size, 0.813; P < .001, and CAM2038, 32 mg: effect size, 0.753; P < .001) and suppression of withdrawal (Clinical Opiate Withdrawal Scale, CAM2038, 24 mg: effect size, 0.617; P < .001, and CAM2038, 32 mg: effect size, 0.751; P < .001). CAM2038 produces a rapid initial rise of buprenorphine in plasma with maximum concentration around 24 hours, with an apparent half-life of 4 to 5 days and approximately 50% accumulation of trough concentration from first to second dose (trough concentration = 0.822 and 1.23 ng/mL for weeks 1 and 2, respectively, with 24 mg; trough concentration = 0.993 and 1.47 ng/mL for weeks 1 and 2, respectively, with 32 mg). CONCLUSIONS AND RELEVANCE: CAM2038 weekly, 24 and 32 mg, was safely tolerated and produced immediate and sustained opioid blockade and withdrawal suppression. The results support the use of this depot formulation for treatment initiation and stabilization of patients with OUD, with the further benefit of obviating the risk for misuse and diversion of daily buprenorphine while retaining its therapeutic benefits. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT02611752.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Walsh SL, Comer SD, Lofwall MR, et al. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017. PMID: 28655025. doi:10.1001/jamapsychiatry.2017.1874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。